We are very pleased to announce the general availability of QIAGEN® Clinical Insight, the most comprehensive, scalable bioinformatics platform for clinical labs interpreting and reporting on genomic variants identified using next-generation sequencing. The first two supported applications are in oncology, for somatic and hereditary cancer testing.
The secure QCI web application rapidly classifies variants, identifies treatment options and performs geographical clinical trial matching. The platform’s interpretation tools are supported by a unique evidence-based approach, which evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical trials. QCI also provides access to the Allele Frequency Community, the world’s largest repository of ancestral and ethnic diversity data.
In creating this platform, we gathered input from more than 100 clinical testing labs and worked with 50 of them to evaluate the QCI content and software in their workflows for laboratory-developed tests. One of the clinical collaborators that evaluated QCI was Dr. Madhuri Hegde, Professor of Human Genetics at the Emory University School of Medicine and Executive Director of the Emory Genetics Laboratory (EGL):
“Clinical labs developing and offering NGS-based clinical tests are confronted with two key challenges: the complexity of translating genetic information into actionable insights for ordering physicians and the time and effort it takes to interpret and report clinically relevant variants. Through its collaboration with EGL and other leading labs on the design and validation of its new QCI offering, QIAGEN has developed a deep understanding of these unmet needs. QCI supports both germline and somatic test indication which is important to labs offering diverse test indications. And it provides full platform and assay agnostic interpretation and reporting workflow support which enables clinical testing labs to reduce time and cost associated with NGS based testing.”
QCI is the latest addition to QIAGEN’s portfolio of bioinformatics solutions that are driving the growth of next-generation sequencing for clinical research and diagnostic labs. For more information on QCI or to request a demo visit our webpage.